ALZNAlzamend Neuro Inc
Mkt Cap
$7.35MVolume
43,093.0052W High
$15.2152W Low
$2.06PE Ratio
-0.27ALZN Fundamentals
Price
$2.33Prev Close
$2.34Open
$2.3350D MA
$2.39Beta
0.81Avg. Volume
122,992.19EPS (Annual)
-$11.32P/B
1.38Rev/Employee
$0.00
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...
Business Wire·8mo ago
Alzamend Neuro to Present at the Sequire Investor Summit
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...
Business Wire·9mo ago
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...
Business Wire·10mo ago
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...
Business Wire·11mo ago
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimers Transgenic Mice
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...
Business Wire·11mo ago
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential
Alzamend Neuro's AL001 study highlights safety and therapeutic potential for Alzheimer's and psychiatric conditions, reducing systemic side effects.
read more...
Benzinga·11mo ago
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...
Business Wire·1y ago
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...
Business Wire·1y ago
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Groups Virtual Healthcare Conference
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...
Business Wire·1y ago